67 related articles for article (PubMed ID: 21945939)
1. Evaluation of human LOX-12 as a serum marker for breast cancer.
Singh AK; Kant S; Parshad R; Banerjee N; Dey S
Biochem Biophys Res Commun; 2011 Oct; 414(2):304-8. PubMed ID: 21945939
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of cyclooxygenase-2 and response to chemotherapy in invasive ductal breast carcinoma patients by real time surface plasmon resonance analysis.
Singh AK; Parshad R; Pasi S; Madhavan T; Das SN; Mishra B; Gill K; Dalal K; Dey S
DNA Cell Biol; 2011 Oct; 30(10):801-7. PubMed ID: 21476934
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
4. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Sakai M; Kato H; Sano A; Tanaka N; Inose T; Kimura H; Sohda M; Nakajima M; Kuwano H
Ann Surg Oncol; 2009 Sep; 16(9):2494-501. PubMed ID: 19526206
[TBL] [Abstract][Full Text] [Related]
5. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
6. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
8. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG; Douglas-Jones AG; Mansel RE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
[TBL] [Abstract][Full Text] [Related]
12. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
[TBL] [Abstract][Full Text] [Related]
13. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
15. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
[TBL] [Abstract][Full Text] [Related]
17. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
18. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
19. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
[TBL] [Abstract][Full Text] [Related]
20. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
